Replies to post #99308 on Biotech Values

[DewDiligence]

Did [BMY] mention anything about their P3 trial for ipi in prostate?

Nope—nothing new to report about the phase-3 HRPC trials in either the first- or second-line settings.

[read_this_n0w]

Patient advocacy group wants to produce and provide drug for their patients

Special cost partnership model that they came up with. Tech transfer from company towards the foundations.

Seems patient advocacy group will try to get drug avaible to patients through their own organisation.

Very interesting concept by PCUT ALS patient group.
Espeically the spread sheet video on their plans.

PCUT newsletter
http://www.pcut.org/index.php?option=com_content&view=article&id=99&Itemid=100

PCUT business model video:
http://www.screencast.com/users/Rabourn/folders/Default/media/96073c26-4e21-4a6a-900a-efc6ec04d129

Or .mov download:
http://home.xmsnet.nl/privatebanking/INSM/PCUT%20Cost%20Partnership%20Model%20.mov